Sanos Group acquires European CRO specializing in Alzheimer's and CNS

Sanos Group is a full-service group in clinical research and development with a special focus on osteoarthritis, musculoskeletal disorders and skin diseases. The Group has gathered all the necessary competencies in clinical development to deliver additional value to pharma and biotech customers through a simple and efficient business model.

"With NeuroScios on board, we are expanding with clinical studies in Alzheimer's disease and thereby expanding our multi-niche CRO with the potential that lies therein. We have long considered the possibilities of expanding our competencies in Alzheimer's disease, and NeuroScios fits perfectly into our model. They have the necessary scientific and operational basis to complement our current specialties with contract research in our established areas of expertise and now with the global full-service capabilities of Sanos Group," says CEO Jeppe Ragnar Andersen, Sanos Group.

NeuroScios is based in Graz, Austria and was established in 2013 by current VP Dr. Manfred Windisch and current CEO Dr. Nikola Helmberg. NeuroScios has 18 employees in the clinical and preclinical areas and with a strong scientific background in biology, psychology and medicine, as well as specialists in medical writing, regulatory affairs and cognitive tests.

The companies complement each other

NeuroScios has conducted and accomplished more than 30 clinical studies in Alzheimer's disease as well as studies in other neurological diseases in phases 1-4. The company comes with a network of top researchers in and outside Austria and with good opportunities to develop new business including a strong pipeline with several projects on the way.

Sanos Group consists of around 200 employees, primarily in Denmark and the United States as well as in Europe and Hong Kong. The Group has four research clinics, including a Phase 1 unit, and the two global full-service CROs NBCD and Blueskin, as well as biostatistics specialists Omicron. In addition, Studies&Me, a unique digital recruitment platform and tech support for clinical studies, and Sanos Supply, which offers contract manufacturing, packaging, labeling, storage and distribution of medicines for clinical studies.

"Like Sanos Group, NeuroScios is thoroughly grounded in scientific excellence, and the activities of the two companies complement each other well, and we see a number of synergies for our overall scientific and business strategy. With NeuroScios on board, Sanos Group will further expand the existing network of international researchers and market opportunities in countries such as Spain, Italy, the Netherlands, Austria and Germany," says CSO of Sanos Group, Asger Reinstrup Bihlet.

NeuroScios will continue unchanged as an independent unit in the Sanos Group with the same name and employees. The company will continue to be led by the two founders, supported by the staff functions of Sanos Group.

Investing in biotech company

As part of the transaction, Sanos Group will also acquire a stake in the biotech company, NSC Therapeutics, which NeuroScios currently owns in part.

The parties have agreed not to disclose further terms of the transaction, including the purchase price. The completion of the transaction is subject to regulatory approval and customary closing conditions.

Additional Info

Group CEO Jeppe Ragnar Andersen, Sanos Group, +45 7370 8223, jra@sanos.com.

About Sanos Group

Sanos Group is a leading specialist provider of clinical study services in the global pharma and biotech industry. The group consists of around 200 employees, mainly in Denmark and the United States, but also in Europe and Hong Kong, and is headquartered in Søborg outside Copenhagen. The group includes Sanos Clinic, which consists of four private research clinics in Denmark, including a Phase 1 unit, the two global full-service CROs NBCD and Blueskin, and Omicron specializing in biostatistics. Studies&Me is a unique digital recruitment platform and tech support for clinical trials. Sanos Supply offers contract manufacturing as well as packaging, labeling, storage and distribution of medicines for clinical studies. Please find more information at www.sanos.com.